JP2017526731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526731A5 JP2017526731A5 JP2017514515A JP2017514515A JP2017526731A5 JP 2017526731 A5 JP2017526731 A5 JP 2017526731A5 JP 2017514515 A JP2017514515 A JP 2017514515A JP 2017514515 A JP2017514515 A JP 2017514515A JP 2017526731 A5 JP2017526731 A5 JP 2017526731A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- methyl
- cancer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 36
- -1 —CF 3 Chemical group 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 14
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 13
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 9
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 9
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 6
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 6
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 6
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 6
- 125000006001 difluoroethyl group Chemical group 0.000 claims 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 6
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- DLGYNVMUCSTYDQ-UHFFFAOYSA-N azane;pyridine Chemical compound N.C1=CC=NC=C1 DLGYNVMUCSTYDQ-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108091052242 Bromo- and Extra-Terminal domain (BET) family Proteins 0.000 claims 1
- WRNSJZMTERMQLP-RWWKDMOOSA-N C(C)(=O)N1C2CN(C(C1)C2)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C Chemical compound C(C)(=O)N1C2CN(C(C1)C2)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C WRNSJZMTERMQLP-RWWKDMOOSA-N 0.000 claims 1
- XGTBENVKMVXFJO-OYHNWAKOSA-N C(C)(=O)N1C[C@@H](N(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C)C Chemical compound C(C)(=O)N1C[C@@H](N(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C)C XGTBENVKMVXFJO-OYHNWAKOSA-N 0.000 claims 1
- OWRSQNNRKFOWNK-VBURHUQHSA-N C(C)(=O)N1C[C@H](N([C@H](C1)C)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C)C Chemical compound C(C)(=O)N1C[C@H](N([C@H](C1)C)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C)C OWRSQNNRKFOWNK-VBURHUQHSA-N 0.000 claims 1
- GHSNBXPTSMIQPL-OYHNWAKOSA-N C(C)(=O)N1[C@H](CN(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C)C Chemical compound C(C)(=O)N1[C@H](CN(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C)C GHSNBXPTSMIQPL-OYHNWAKOSA-N 0.000 claims 1
- CPKBVGXUMOILKV-JOCHJYFZSA-N C(CCC)(=O)N1CCN(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C Chemical compound C(CCC)(=O)N1CCN(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C CPKBVGXUMOILKV-JOCHJYFZSA-N 0.000 claims 1
- KFVXVHFSAAIXQI-JOCHJYFZSA-N C1(CC1)C(=O)N1CCN(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C Chemical compound C1(CC1)C(=O)N1CCN(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C KFVXVHFSAAIXQI-JOCHJYFZSA-N 0.000 claims 1
- HWZQFCPIMIHIHR-HSZRJFAPSA-N C1(CCC1)C(=O)N1CCN(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C Chemical compound C1(CCC1)C(=O)N1CCN(CC1)C1=NC2=CC=C(C3=C2N1[C@H](CO3)C1=NC=CC=C1)C=1C(=NOC=1C)C HWZQFCPIMIHIHR-HSZRJFAPSA-N 0.000 claims 1
- LSAGBYDJYRHTRW-JOCHJYFZSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)(C)NC(C)=O)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)(C)NC(C)=O)C LSAGBYDJYRHTRW-JOCHJYFZSA-N 0.000 claims 1
- URTLKQGQGJOMMK-XMMPIXPASA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(=O)C1CC1)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(=O)C1CC1)C)C URTLKQGQGJOMMK-XMMPIXPASA-N 0.000 claims 1
- SATUWZAHXGFNLD-RUZDIDTESA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(=O)C1CCC1)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(=O)C1CCC1)C)C SATUWZAHXGFNLD-RUZDIDTESA-N 0.000 claims 1
- WGVACKKKDBPNCF-HSZRJFAPSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(=O)N(C)C)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(=O)N(C)C)C)C WGVACKKKDBPNCF-HSZRJFAPSA-N 0.000 claims 1
- HHQXLCQBSIIXEP-XMMPIXPASA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(C(C)(C)C)=O)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(C(C)(C)C)=O)C)C HHQXLCQBSIIXEP-XMMPIXPASA-N 0.000 claims 1
- APUQYQHFLNFUIV-XMMPIXPASA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(C(C)C)=O)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(C(C)C)=O)C)C APUQYQHFLNFUIV-XMMPIXPASA-N 0.000 claims 1
- KQJJFAFXMLVFRW-HSZRJFAPSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(C)=O)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(C)=O)C)C KQJJFAFXMLVFRW-HSZRJFAPSA-N 0.000 claims 1
- KGXSUEGVKXWRQI-HSZRJFAPSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(CC)=O)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(CC)=O)C)C KGXSUEGVKXWRQI-HSZRJFAPSA-N 0.000 claims 1
- ADEWRUVSNLFKIT-XMMPIXPASA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(CCC)=O)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(C(CCC)=O)C)C ADEWRUVSNLFKIT-XMMPIXPASA-N 0.000 claims 1
- SAVAOMJTQJFGSR-JOCHJYFZSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(S(=O)(=O)C)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(S(=O)(=O)C)C)C SAVAOMJTQJFGSR-JOCHJYFZSA-N 0.000 claims 1
- SPOSSZBPBDNJNT-XMMPIXPASA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(S(=O)(=O)C1CC1)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)N(S(=O)(=O)C1CC1)C)C SPOSSZBPBDNJNT-XMMPIXPASA-N 0.000 claims 1
- DUPQOQJOCVRTBS-HSZRJFAPSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NC(=O)C1CC1)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NC(=O)C1CC1)C DUPQOQJOCVRTBS-HSZRJFAPSA-N 0.000 claims 1
- PUJWPYZXZNJVIG-XMMPIXPASA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NC(=O)C1CCC1)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NC(=O)C1CCC1)C PUJWPYZXZNJVIG-XMMPIXPASA-N 0.000 claims 1
- AOHRCIHLNZGGEC-HSZRJFAPSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NC(C(C)(C)C)=O)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NC(C(C)(C)C)=O)C AOHRCIHLNZGGEC-HSZRJFAPSA-N 0.000 claims 1
- OTNSFSFYTFKMEB-HSZRJFAPSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NC(CCC)=O)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NC(CCC)=O)C OTNSFSFYTFKMEB-HSZRJFAPSA-N 0.000 claims 1
- SJGWGZCUULTQIO-JOCHJYFZSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NS(=O)(=O)CC)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCC(CC1)NS(=O)(=O)CC)C SJGWGZCUULTQIO-JOCHJYFZSA-N 0.000 claims 1
- CYANTQDGHUIJGZ-JOCHJYFZSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCN(CC1)C(C(C)(C)C)=O)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCN(CC1)C(C(C)(C)C)=O)C CYANTQDGHUIJGZ-JOCHJYFZSA-N 0.000 claims 1
- OZALPVLVYBXRKE-JOCHJYFZSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCN(CC1)C(C(C)C)=O)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCN(CC1)C(C(C)C)=O)C OZALPVLVYBXRKE-JOCHJYFZSA-N 0.000 claims 1
- QQLIQKOWTUKCCX-OAQYLSRUSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCN(CC1)C(COC)=O)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1CCN(CC1)C(COC)=O)C QQLIQKOWTUKCCX-OAQYLSRUSA-N 0.000 claims 1
- QVFNWZZKUKTJTE-GAJHUEQPSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1C[C@@H](N(CC1)C(C(C)C)=O)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1C[C@@H](N(CC1)C(C(C)C)=O)C)C QVFNWZZKUKTJTE-GAJHUEQPSA-N 0.000 claims 1
- DGRMYTISESUMFZ-KSFYIVLOSA-N CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1C[C@@H](N(CC1)C(CC)=O)C)C Chemical compound CC1=NOC(=C1C1=CC=C2C=3N([C@H](COC=31)C1=NC=CC=C1)C(=N2)N1C[C@@H](N(CC1)C(CC)=O)C)C DGRMYTISESUMFZ-KSFYIVLOSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 208000027500 optic nerve neoplasm Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050500P | 2014-09-15 | 2014-09-15 | |
| US62/050,500 | 2014-09-15 | ||
| PCT/US2015/049909 WO2016044130A1 (en) | 2014-09-15 | 2015-09-14 | Tricyclic heterocycles for use as bet protein inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526731A JP2017526731A (ja) | 2017-09-14 |
| JP2017526731A5 true JP2017526731A5 (enExample) | 2018-10-25 |
| JP6599979B2 JP6599979B2 (ja) | 2019-10-30 |
Family
ID=54207768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514515A Active JP6599979B2 (ja) | 2014-09-15 | 2015-09-14 | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9527864B2 (enExample) |
| EP (1) | EP3194406B8 (enExample) |
| JP (1) | JP6599979B2 (enExample) |
| ES (1) | ES2855225T3 (enExample) |
| TW (1) | TWI712603B (enExample) |
| WO (1) | WO2016044130A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| WO2017075377A1 (en) * | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| US11535633B2 (en) * | 2018-06-28 | 2022-12-27 | Jiangsu Hengrui Medicine Co., Ltd. | Fused tricyclic heterocycle compounds and therapeutic uses thereof |
| AU2019326633B2 (en) * | 2018-08-24 | 2022-09-08 | Adlai Nortye Biopharma Co., Ltd. | High activity sting protein agonist |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59170313A (ja) | 1983-03-14 | 1984-09-26 | Kurimoto Iron Works Ltd | スクリ−ンゲ−ト |
| JPS6085739U (ja) | 1983-11-18 | 1985-06-13 | クラリオン株式会社 | テ−プレコ−ダにおけるピンチロ−ラ装置 |
| JPH0314566A (ja) | 1989-06-09 | 1991-01-23 | Sankyo Co Ltd | ベンズイミダゾール誘導体 |
| US5244912A (en) | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
| FR2710915B1 (fr) | 1993-10-04 | 1995-11-24 | Synthelabo | Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique. |
| FR2731708B1 (fr) * | 1995-03-13 | 1997-04-30 | Synthelabo | Derives de piperidine, leur procede de preparation et leur application en therapeutique |
| FR2747678B1 (fr) | 1996-04-22 | 1998-05-22 | Synthelabo | Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique |
| CN1450898A (zh) | 2000-04-21 | 2003-10-22 | 法玛西雅厄普约翰美国公司 | 用于治疗纤维肌痛和慢性疲劳综合症的化合物 |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| US6919334B2 (en) * | 2002-09-12 | 2005-07-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine |
| RU2342388C2 (ru) | 2002-11-22 | 2008-12-27 | Джапан Тобакко Инк. | Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием |
| EP1462103A1 (en) | 2003-03-25 | 2004-09-29 | Faust Pharmaceuticals | NO donors, combination products and uses as modulators of neurotransmitter release |
| CN1922141A (zh) | 2004-02-23 | 2007-02-28 | 大日本住友制药株式会社 | 新的杂环化合物 |
| EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
| DE102005011058A1 (de) | 2005-03-10 | 2006-09-14 | Merck Patent Gmbh | Substituierte Tetrahydro-pyrrolo-chinolinderivate |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| US20070032469A1 (en) * | 2005-08-05 | 2007-02-08 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| EP2147310A4 (en) | 2007-04-27 | 2010-09-08 | Univ Rochester | COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| WO2009020559A2 (en) | 2007-08-03 | 2009-02-12 | The J. David Gladstone Institutes | Agents that inhibit p-tefb interactions and methods of use thereof |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| DE102008052618A1 (de) | 2008-10-21 | 2010-04-22 | Henkel Ag & Co. Kgaa | Tricyclische Aldehyde und C,H-acide Verbindungen |
| WO2010111626A2 (en) | 2009-03-27 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| TW201103941A (en) | 2009-06-10 | 2011-02-01 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| TW201105681A (en) | 2009-06-10 | 2011-02-16 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| WO2011024987A1 (ja) | 2009-08-31 | 2011-03-03 | 塩野義製薬株式会社 | 芳香族縮合へテロ環誘導体およびそれらを含有する医薬組成物 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP3050885B1 (en) | 2009-11-05 | 2017-10-18 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| WO2011054851A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AU2010314395B2 (en) | 2009-11-05 | 2015-04-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| KR20130069640A (ko) | 2010-04-23 | 2013-06-26 | 키네타, 인크. | 항-바이러스 화합물 |
| EP2571875A4 (en) | 2010-05-14 | 2013-10-30 | Dana Farber Cancer Inst Inc | CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| CN103119160B (zh) | 2010-05-14 | 2016-06-01 | 达那-法伯癌症研究所 | 用于调节代谢的组合物和方法 |
| JP5844358B2 (ja) | 2010-06-22 | 2016-01-13 | グラクソスミスクライン エルエルシー | ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| RU2013138835A (ru) | 2011-02-09 | 2015-03-20 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения в качестве ингибиторов pi3 киназы |
| AU2012220620A1 (en) | 2011-02-23 | 2013-10-03 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106799D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US20150197497A1 (en) | 2011-06-24 | 2015-07-16 | Dana-Farber Cancer Institute, Inc. | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| CA2843643A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| SG2014004162A (en) | 2011-08-31 | 2014-03-28 | Otsuka Pharma Co Ltd | Quinolone compound |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| EP2757887B1 (en) | 2011-09-22 | 2017-04-26 | VIIV Healthcare UK Limited | Pyrrolopyridinone compounds and methods for treating hiv |
| WO2013044511A1 (zh) | 2011-09-30 | 2013-04-04 | 沈阳蓝桑医药生物技术研发有限公司 | 含有瑞利格内酯的药物组合物及其应用 |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013148197A1 (en) | 2012-03-28 | 2013-10-03 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281396A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CA2870931A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
| US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| AU2012382373A1 (en) | 2012-06-12 | 2014-12-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
| AU2013283378B2 (en) | 2012-06-25 | 2017-07-13 | Oncoethix Gmbh | Method of treating lymphoma using thienotriazolodiazepine compounds |
| US9610332B2 (en) | 2012-07-18 | 2017-04-04 | Massachusetts Institute Of Technology | Compositions and methods for modulating BRD4 bioactivity |
| EP2885286B1 (de) | 2012-08-16 | 2017-03-22 | Bayer Pharma Aktiengesellschaft | 2,3-benzodiazepine |
| JP2015524847A (ja) | 2012-08-16 | 2015-08-27 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 小細胞肺がんを治療するためのベンゾジアゼピン |
| EP2900672B1 (de) | 2012-09-28 | 2017-02-22 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 5-aryl-triazolo-azepine |
| JP2015531365A (ja) | 2012-09-28 | 2015-11-02 | オンコエシックス エスエー | チエノトリアゾロジアゼピン化合物を含む医薬製剤 |
| US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
| ES2625945T3 (es) | 2012-11-14 | 2017-07-21 | Glaxosmithkline Llc | Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| CA2895426A1 (en) | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydroquinoxalinones |
| CN105229002A (zh) | 2012-12-20 | 2016-01-06 | 拜耳医药股份有限公司 | 抑制bet蛋白的二氢吡啶并吡嗪酮 |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| EP2961747B1 (en) | 2013-02-27 | 2017-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| MX2015012158A (es) | 2013-03-11 | 2015-12-01 | Abbvie Inc | Inhibidores de bomodominio tetraciclicos fusionados. |
| US9050346B2 (en) | 2013-03-11 | 2015-06-09 | Abbvie Inc. | Bromodomain inhibitors |
| BR112015022551A2 (pt) | 2013-03-12 | 2017-07-18 | Abbvie Inc | inibidores de amido pirrol |
| UY35395A (es) | 2013-03-12 | 2014-10-31 | Abbvie Inc | Inhibidores de bromodominios tetracíclicos |
| BR112015022643A2 (pt) | 2013-03-12 | 2017-07-18 | Abbvie Inc | inibidores diidro-pirrolpiridinona |
| HUE043568T2 (hu) | 2013-03-14 | 2019-08-28 | Glaxosmithkline Ip No 2 Ltd | 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| US9670221B2 (en) | 2013-03-14 | 2017-06-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Furopyridines as bromodomain inhibitors |
| CA2904364A1 (en) | 2013-03-15 | 2014-09-25 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
| DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| JP6370368B2 (ja) | 2013-03-27 | 2018-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｒｄ４阻害剤としてのインドリノン類似体 |
| JP6453845B2 (ja) | 2013-03-27 | 2019-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体 |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| EP2996689A1 (en) | 2013-04-17 | 2016-03-23 | Albert-Ludwigs-Universität Freiburg | Compounds for use as bromodomain inhibitors |
| US9393232B2 (en) | 2013-04-26 | 2016-07-19 | Beigene, Ltd. | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| EP3412675A1 (en) | 2013-05-27 | 2018-12-12 | Novartis AG | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| MX2015016421A (es) | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
| AU2014272700B2 (en) | 2013-05-28 | 2016-12-01 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
| WO2014202578A1 (de) | 2013-06-17 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituierte phenyl-2,3-benzodiazepine |
| ITMI20130991A1 (it) | 2013-06-17 | 2014-12-18 | Industrie De Nora Spa | Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse. |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| JP6461118B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
| WO2014206150A1 (en) | 2013-06-28 | 2014-12-31 | Abbvie Inc. | Bromodomain inhibitors |
| AR096758A1 (es) | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| BR112015033042B1 (pt) | 2013-07-16 | 2020-10-13 | Basf Se | composto de azina, processos para a preparação de composto de azina, composição agroquímica, processo para a preparação de composições agroquímicas, método para controlar vegetação e uso do composto de azina |
| US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| KR101672096B1 (ko) | 2013-09-30 | 2016-11-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
| SG10201804471PA (en) | 2013-10-18 | 2018-07-30 | Celgene Quanticel Research Inc | Bromodomain inhibitors |
| WO2015081246A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| EP3089970B1 (en) | 2013-12-09 | 2018-10-17 | AbbVie Inc. | Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US9822107B2 (en) | 2013-12-20 | 2017-11-21 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| HUE041546T2 (hu) | 2014-01-09 | 2019-05-28 | Orion Corp | Biciklusos heterociklusos származékvegyületek mint bromo doméninhibitorok |
| WO2015131005A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| JP6538077B2 (ja) | 2014-04-23 | 2019-07-03 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 除草剤としてのジアミノトリアジン化合物 |
| DK3134386T3 (da) | 2014-04-23 | 2020-08-17 | Takeda Pharmaceuticals Co | Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| US20170095484A1 (en) | 2014-05-02 | 2017-04-06 | Oncoethix Gmbh | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
| EP3137085A4 (en) | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
| AU2015257658A1 (en) | 2014-05-08 | 2016-11-10 | Oncoethix Gmbh | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
| WO2015169953A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
| EP3148543B1 (en) | 2014-05-30 | 2020-04-08 | Icahn School of Medicine at Mount Sinai | Small molecule transcription modulators of bromodomains |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| CN105029258A (zh) | 2014-09-20 | 2015-11-11 | 林静 | 一种多味橄榄的制作方法 |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| US10259809B2 (en) | 2015-02-03 | 2019-04-16 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins |
| WO2016186453A1 (en) | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
| TWI700284B (zh) | 2015-05-29 | 2020-08-01 | 日商塩野義製藥股份有限公司 | 具有ｈｉｖ複製抑制作用之含氮３環性衍生物 |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CN105254635A (zh) | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
| US20170127985A1 (en) | 2015-11-11 | 2017-05-11 | Medtronic Minimed, Inc. | Sensor set |
| WO2017103670A1 (en) | 2015-12-14 | 2017-06-22 | Zenith Epigenetics Lid. | 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| US20190040063A1 (en) | 2016-02-05 | 2019-02-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| CN108069958A (zh) | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
-
2015
- 2015-09-14 JP JP2017514515A patent/JP6599979B2/ja active Active
- 2015-09-14 EP EP15771373.6A patent/EP3194406B8/en active Active
- 2015-09-14 US US14/852,958 patent/US9527864B2/en active Active
- 2015-09-14 WO PCT/US2015/049909 patent/WO2016044130A1/en not_active Ceased
- 2015-09-14 TW TW104130337A patent/TWI712603B/zh active
- 2015-09-14 ES ES15771373T patent/ES2855225T3/es active Active
-
2016
- 2016-11-18 US US15/356,002 patent/US9834565B2/en not_active Expired - Fee Related
-
2017
- 2017-11-02 US US15/802,142 patent/US10227359B2/en active Active
-
2019
- 2019-02-01 US US16/265,450 patent/US10618910B2/en active Active